{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T13:30:36Z","timestamp":1776951036254,"version":"3.51.4"},"reference-count":46,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"European Union Next-Generation EU","award":["2.004-0004-C01"],"award-info":[{"award-number":["2.004-0004-C01"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Background: In recent years, musculoskeletal ultrasonography (MSUS) has established itself as a reliable method for evaluating disease activity in combination with clinical examination and laboratory tests. Objectives: In this pilot study, we aimed to evaluate the ultrasound response to treatment with tofacitinib and upadacitinib on tendons and joints in comparison to clinical and laboratory results in patients with RA who have shown inadequate response to conventional synthetic and\/or biologic disease-modifying antirheumatic drugs (cs\/b DMARDs). Methods: This study presents the MSUS assessment of therapeutic response in RA patients treated with tofacitinib or upadacitinib over a 24-week period. In a prospective, single-center study, patients were treated with upadacitinib 15 mg\/daily or tofacitinib 2 \u00d7 5 mg\/daily or 11 mg\/daily, in combination with or without methotrexate or another conventional DMARDs. Disease activity was assessed by DAS28-CRP, CDAI, and SDAI, as well as MSUS. Patients were evaluated at baseline for ultrasound measures and at weeks 2, 4, 8, 12, and 24 for the rest of the indicators. For each patient, we used two ultrasound (US) scores (gray-scale, GS, and power Doppler, PD scores) and the system of European Alliance of Associations for Rheumatology outcome measures in rheumatology (EULAR-OMERACT) US scoring (combined GS and PD). We also calculated the tenosynovitis score (GS and PD) according to OMERACT recommendations. Results: A total of 53 patients were recruited. A total of 25 patients with a mean age of 56 \u00b1 11.6 SD were followed in the upadacitinib group, and 22 patients with a mean age of 56.9 \u00b1 11.3 were followed in the tofacitinib group. At baseline, DAS28-CRP for the upadacitinib group was 5.57 \u00b1 1.24, and for tofacitinib, it was 4.77 \u00b1 1.47. The baseline visit (GS, PD, and combined\u2014US) and tendon US scores (GS and PD) were, respectively, 23 \u00b1 2.96, 15 \u00b1 2.56, 24.08 \u00b1 3.36, 11.04 \u00b1 2.21, and 8.44 \u00b1 1.65 for the upadacitinib group. USGS-J\u201423 \u00b1 3.55, USPD-J\u201413.36 \u00b1 2.44, OMERACT composite\u201423.4 \u00b1 3.84, USGS-T\u201412.18 \u00b1 2.23, and USPD-T\u20149.5 \u00b1 1.92 were found in the patients treated with tofacitinib. In both groups of patients, a significant reduction was found in both DAS28-CRP and the described MSUS scores at weeks 8, 12, and 24 (p &lt; 0.05). Conclusions: Upadacitinib managed to produce lower echography scores much faster than tofacitinib; however, the differences in effectiveness evened out at weeks 12 and 24, with all patients being adequately controlled.<\/jats:p>","DOI":"10.3390\/biomedicines13061339","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T06:14:27Z","timestamp":1748585667000},"page":"1339","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Ultrasound Evaluation of Therapeutic Response to Tofacitinib and Upadacitinib in Patients with Rheumatoid Arthritis\u2014Real-Life Clinical Data"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6780-5810","authenticated-orcid":false,"given":"Vladimira","family":"Boyadzhieva","sequence":"first","affiliation":[{"name":"Department of Rheumatology, University Hospital \u201cSt. Iv. Rilski\u201d, Medical University of Sofia, 1612 Sofia, Bulgaria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantin","family":"Tachkov","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Medical University of Sofia, 1000 Sofia, Bulgaria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soner","family":"Emin","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University Hospital \u201cSt. Iv. Rilski\u201d, Medical University of Sofia, 1612 Sofia, Bulgaria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaklin","family":"Apostolova","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, Rheumatology Clinic, UMBAL \u201cSt. Marina\u201d\u2014Varna, Medical University of Varna, 9010 Varna, Bulgaria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rumen","family":"Stoilov","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University Hospital \u201cSt. Iv. Rilski\u201d, Medical University of Sofia, 1612 Sofia, Bulgaria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8116-5138","authenticated-orcid":false,"given":"Guenka","family":"Petrova","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Medical University of Sofia, 1000 Sofia, Bulgaria"},{"name":"Research Institute of Innovative Medical Sciences \u201cInnoMedSci\u201d, 1431 Sofia, Bulgaria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolay","family":"Stoilov","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University Hospital \u201cSt. Iv. Rilski\u201d, Medical University of Sofia, 1612 Sofia, Bulgaria"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,30]]},"reference":[{"key":"ref_1","first-page":"3","article-title":"Treatment of rheumatoid arthritis: csDMARDS versus bDMARDS. Prospective study to evaluate disease activity","volume":"27","author":"Boyadzhieva","year":"2019","journal-title":"Rheumatology"},{"key":"ref_2","first-page":"29","article-title":"Assessment of health-related quality of life in patients with rheumatoid arthritis and analysis of its change during csDMARDS and bDMARDS therapy after one year of follow-up","volume":"27","author":"Boyadzhieva","year":"2019","journal-title":"Rheumatology"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Tachkov, K., Boyadzhieva, V., Stoilov, N., Mitov, K., and Petrova, G. (2021). Is There a Symmetry in Disease Control and Quality of Life of Patients with Rheumatoid Arthritis Treated with Biological Therapy?. Symmetry, 13.","DOI":"10.3390\/sym13040538"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1136\/ard.2009.123919","article-title":"Treating rheumatoid arthritis to target: Recommendations of an international task force","volume":"69","author":"Smolen","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.39480","article-title":"2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"ref_6","unstructured":"National Institute for Health and Clinical Excellence (NICE) (2009). 2 Rheumatoid Arthritis: The Management of Rheumatoid Arthritis in Adults, National Collaborating Centre for Chronic Conditions."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/s41584-019-0170-5","article-title":"Treat-to-target in rheumatoid arthritis\u2014Are we there yet?","volume":"15","year":"2019","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/j.clinthera.2017.06.013","article-title":"Systematic literature review and meta-analysis of tumor necrosis factor-alpha experienced rheumatoid arthritis","volume":"39","author":"Wells","year":"2017","journal-title":"Clin. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.pharmthera.2007.10.001","article-title":"Tumor necrosis factor antagonist mechanisms of action: A comprehensive review","volume":"117","author":"Tracey","year":"2008","journal-title":"Pharmacol. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","article-title":"Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): A phase 3b\/4, double- blind, head-to-head, randomised controlled trial","volume":"390","author":"Fleischmann","year":"2017","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1002\/art.40803","article-title":"Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: Clinical efficacy, radiographic, and safety outcomes from a twenty-four-month, phase III study","volume":"71","author":"Strand","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e000806","DOI":"10.1136\/rmdopen-2018-000806","article-title":"Tofacitinib or adalimumab versus placebo: Patient-reported outcomes from OPAL Broaden-a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs","volume":"5","author":"Strand","year":"2019","journal-title":"RMD Open"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1136\/annrheumdis-2016-210105","article-title":"Filgotinib (GLPG0634\/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: Results from a randomised, dose-finding study (DARWIN 2)","volume":"76","author":"Kavanaugh","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","article-title":"Baricitinib in patients with refractory rheumatoid arthritis","volume":"374","author":"Genovese","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"P2513","DOI":"10.1016\/S0140-6736(18)31116-4","article-title":"Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying antirheumatic drugs (SELECT-BEYOND): A double-blind, randomised controlled phase 3 trial","volume":"391","author":"Genovese","year":"2018","journal-title":"Lancet"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1016\/S0140-6736(18)31115-2","article-title":"Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): A randomised, double-blind, placebo-controlled phase 3 trial","volume":"391","author":"Burmester","year":"2018","journal-title":"Lancet"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s00108-019-0591-x","article-title":"Upadacitinib bei Patienten mit rheumatoider Arthritis: SELECT-NEXT und SELECT-BEYOND. (Upadacitinib in patients with rheumatoid arthritis: SELECT-NEXT and SELECT-BEYOND)","volume":"60","author":"Nitschmann","year":"2019","journal-title":"Internist"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1016\/S0140-6736(19)30419-2","article-title":"Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): A randomised, placebo-controlled, double-blind phase 3 study","volume":"393","author":"Smolen","year":"2019","journal-title":"Lancet"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"German\u00f2, G., Macchioni, P., Maranini, B., Ciancio, G., Bonazza, S., Govoni, M., and Salvarani, C. (2022). Ultrasound response to tofacitinib in patients with rheumatoid arthritis: Data from a multicenter 24 weeks prospective study. Front. Med., 9.","DOI":"10.3389\/fmed.2022.990317"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1136\/annrheumdis-2019-215764","article-title":"Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response","volume":"78","author":"Fleischmann","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"ref_21","unstructured":"(2021, January 15). The DAS28 Score. Available online: https:\/\/nras.org.uk\/resource\/the-das28-score\/."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that include twenty-eight\u2013joint counts: Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis","volume":"38","author":"Prevoo","year":"1995","journal-title":"Arthritis Rheum."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/rheumatology\/keg072","article-title":"A simplified disease activity index for rheumatoid arthritis for use in clinical practice","volume":"42","author":"Smolen","year":"2003","journal-title":"Rheumatology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"253","DOI":"10.7326\/0003-4819-159-4-201308200-00006","article-title":"Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: A randomized trial","volume":"159","author":"Kremer","year":"2013","journal-title":"Ann. Intern. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e000427","DOI":"10.1136\/rmdopen-2016-000427","article-title":"Scoring ultrasound synovitis in rheumatoid arthritis: A EULAR OMERACT ultrasound taskforce-Part 2: Reliability and application to multiple joints of a standardised consensus-based scoring system","volume":"3","author":"Terslev","year":"2017","journal-title":"RMD Open"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Razmjou, A.A., Brook, J., Elashoff, D., Kaeley, G., Choi, S., Kermani, T., and Ranganath, V.K. (2020). Ultrasound and multi-biomarker disease activity score for assessing and predicting clinical response to tofacitinib treatment in patients with rheumatoid arthritis. BMC Rheumatol., 4.","DOI":"10.1186\/s41927-020-00153-4"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11926-020-00911-w","article-title":"The Role of Musculoskeletal Ultrasound in the Rheumatoid Arthritis Continuum","volume":"22","author":"Mankia","year":"2020","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1016\/j.ultrasmedbio.2020.04.015","article-title":"The Role of Musculoskeletal Ultrasound Imaging in Rheumatoid Arthritis","volume":"46","author":"Elangovan","year":"2020","journal-title":"Ultrasound Med. Biol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1136\/ard.2011.149765","article-title":"American college of rheumatology\/European league against rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials","volume":"70","author":"Felson","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"ref_30","first-page":"1316","article-title":"The role of imaging in rheumatoid arthritis","volume":"22","author":"Kgoebane","year":"2018","journal-title":"SA J. Radiol."},{"key":"ref_31","unstructured":"National Council of Prices and Reimbursement of Medicines (2025, May 14). Pharmacotherapeutic Guideline on Rheumatology. Available online: https:\/\/www.ncpr.bg\/images\/farmako-terapevtichni\/2019\/01.04.2019\/ftr_po_revmatologiia.pdf."},{"key":"ref_32","unstructured":"National Health Insurance Fund (2025, May 14). Requirements for Rheumatology. Available online: https:\/\/www.nhif.bg\/upload\/22768\/18.%D0%98%D0%B7%D0%B8%D1%81%D0%BA%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F%20%D0%BD%D0%B0%20%D0%9D%D0%97%D0%9E%D0%9A%20%20%D1%80%D0%B5%D0%B2%D0%BC%D0%B0%D1%82%D0%BE%D0%BB%D0%BE%D0%B3%D0%B8%D1%8F.pdf."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1001\/jama.2018.13103","article-title":"Diagnosis and management of rheumatoid arthritis: A review","volume":"320","author":"Aletaha","year":"2018","journal-title":"JAMA"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Sanmart\u00ed, R., and Corominas, H. (2023). Upadacitinib for Patients with Rheumatoid Arthritis: A Comprehensive Review. J. Clin. Med., 12.","DOI":"10.3390\/jcm12051734"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2147\/JIR.S219586","article-title":"JAK Inhibitors in Rheumatoid Arthritis: An Evidence-Based Review on the Emerging Clinical Data","volume":"13","author":"Harrington","year":"2020","journal-title":"J. Inflamm. Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1002\/art.41384","article-title":"Efficacy and safety of upadacitinib monotherapy in methotrexate-na\u00efve patients with moderately to severely active rheumatoid arthritis (SELECT-EARLY): A randomized, double-blind, active-comparator, multi-center, multi-country trial","volume":"72","author":"Takeuchi","year":"2020","journal-title":"Arthritis Rheumatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1056\/NEJMoa2008250","article-title":"Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis","volume":"383","author":"Enejosa","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_38","first-page":"1011","article-title":"Efficacy and safety of upadacitinib versus abatacept in patients with active rheumatoid arthritis and prior inadequate response or intolerance to biologic disease-modifying anti-rheumatic drugs (SELECT-CHOICE): A double-blind, rnadomized controlled Phase 3 trial","volume":"79","author":"Enejosa","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s10067-016-3436-1","article-title":"Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group","volume":"36","author":"Fleischmann","year":"2017","journal-title":"Clin. Rheum."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1136\/annrheumdis-2012-201970","article-title":"Rituximab dissociates the tight link between disease activity and joint damage in rheumatoid arthritis patients","volume":"72","author":"Aletaha","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","article-title":"Tofacitinib versus methotrexate in rheumatoid arthritis","volume":"370","author":"Lee","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_42","first-page":"1788","article-title":"A phase 3, randomized, double-blind study comparing upadacitinib to placebo and to adalimumab, in patients with active rheumatoid arthritis with inadequate response to methotrexate","volume":"70","author":"Fleischmann","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1093\/rheumatology\/kem383","article-title":"The relation between composite ultrasound measures and the DAS28 score, its components and acute phase markers in adult RA","volume":"47","author":"Hameed","year":"2008","journal-title":"Rheumatology"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Baldi, C., Parisi, S., Falsetti, P., Sota, J., Ditto, M.C., Capassoni, M., D\u2019alessandro, M., Conticini, E., Nacci, F., and Peroni, C.L. (2024). Efficacy and Safety of Upadacitinib in Rheumatoid Arthritis: Real-Life Experience from a Prospective Longitudinal Multicentric Study. J. Clin. Med., 13.","DOI":"10.3390\/jcm13020401"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1007\/s40744-024-00712-y","article-title":"Clinical and Ultrasonographic Remission in Bio-na\u00efve and Bio-failure Patients with Rheumatoid Arthritis at 24 Weeks of Upadacitinib Treatment: The UPARAREMUS Real-Life Study","volume":"11","author":"Cattaruzza","year":"2024","journal-title":"Rheumatol. Ther."},{"key":"ref_46","first-page":"921","article-title":"The role of musculoskeletal ultrasound in predicting the response to JAK inhibitors: Results from a monocentric cohort","volume":"40","author":"Ceccarelli","year":"2022","journal-title":"Clin. Exp. Rheumatol."}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/13\/6\/1339\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:43:47Z","timestamp":1760031827000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/13\/6\/1339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,30]]},"references-count":46,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["biomedicines13061339"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines13061339","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,30]]}}}